Cori Vail has been elected as the ILF industry representative. Cori currently leads HIV Access Strategy & Impact efforts as part of Johnson & Johnson’s Global Public Health team. In this role, she is responsible for developing and executing insight-based strategies to accelerate adoption of transformational HIV innovation for underserved populations in resource-limited settings. Cori joined the Johnson & Johnson family of companies in 2003 and held numerous roles across engineering, operations, and new product development and implementation before transitioning to global public health in 2015.
“Johnson & Johnson welcomes this opportunity to collaborate, on behalf of industry, with a diverse group of partners to advance our collective goal of preventing new HIV infections and ensuring more people with HIV receive the care they need,” Cori said. “With COVID-19 threatening to reverse the tremendous gains that have been made in the HIV space, now is a critical time for all of us – across all sectors – to think more creatively than ever before so we can build on our past successes and ensure continued progress against this epidemic.”
Dr Anton Pozniak, Immediate Past President of IAS has been appointed as the ILF non-industry representative. Anton is a Consultant Physician in HIV Medicine at the Chelsea and Westminster Hospital and Professor in the Department of Clinical Research at the London School of Hygiene and Tropical Medicine.
“The ILF has a breadth of knowledge and skills which allows it to play a crucial role in highlighting important biomedical issues that define the HIV response,” Anton said. “I am looking forward to being part of this dynamic group.”
Established in 2003, the ILF promotes and facilitates the important contribution of the biomedical industry to the HIV response by catalysing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum. Cori and Anton’s leadership will prove key as the ILF, following a strategic review of activities in late 2019, embarks on a new phase in its work that reflects current challenges in the HIV response, many of which have been exacerbated by the COVID-19 pandemic.
The IAS would like to thank Duncan Blair and Jürgen Rockstroh, outgoing ILF co-chairs, for their leadership and contribution to the ILF, including their stewardship of the ILF strategic review in 2019.
For more information about the ILF, visit www.iasociety.org/ilf.
| Tags: | View Count: (2602) | Return